About
About Bionano Genomics, Inc
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Visit company website
5 years, 5 months ago
Bionano Genomics, Inc is currently in a long term uptrend where the price is trading 18.6% above its 200 day moving average.
From a valuation standpoint, the stock is 93.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 92.4.
Bionano Genomics, Inc's total revenue rose by 43.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 48.5% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.3% to $-12M since the same quarter in the previous year.
Based on the above factors, Bionano Genomics, Inc gets an overall score of 3/5.